Abbott's strategy to expand its EPD business through a capital-efficient licensing model is likely to positively impact its stock. This approach not only supports revenue growth by tapping into emerging markets but also positions Abbott as a leader in providing access to essential medicines, which is crucial amid macroeconomic challenges.